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Studies of the inhibition of elastases at a molecular level have resulted in the identification of protected 
dipeptides which are reversible and highly specific inhibitors of human leucocyte lastase (HLE). These have 
been further developed by increasing their hydroph~~icity and potency to give a new family of eiastase inhibi- 
tors, typicaly ND--( 1-adamantanesulphonyl)-N~-(4-carboxybenzoyl)-L-Iysy~-~-a~anyl-L-va~inal. These com- 
pounds are active in pharmacological models designed to detect compounds of potential therapeutic value 
in the treatment of emphysema. 
Elastase Inhibitor Design Emphysema 
1. INTRODUCTION 2. EXP~RI~E~AL 
There is a good basis for suggesting that specific 
inhibitors of human elastase may have value in 
medicine. It has been shown that pulmonary em- 
physema results from degradation of alveolar wall 
elastin during periods when human leucocyte 
elastase (HLE, EC 3.4.2.11) released in the lung is 
inadequately controlled by endogenous inhibitors 
[1,2,3]. In these circumstances, further lung 
degradation could be prevented by prophylactic 
replacement herapy with a low-M, synthetic in- 
hibitor of HLE. Elastase occurs in lysosomes and 
probably plays an important role in inflammatory 
processes involving other than lung tissues [4]. 
The synthesis of the typical inhibitor, W- 
(1 -adamantanesulphonyl)-N”-(4-carboxybenzoyI)- 
L-lysyl-L-alanyl-L-valinal is outlined in fig. 1. Ex- 
perimental details relating to the chemistry, 
biochemistry and pharmacology of this and related 
compounds will be provided in later publications, 
Computer graphics utilised a Megatek 7000 
display processor interfaced to a VAX 1 l/750 
computer and a Calcomp 81 plotter. 
HLE was purified from leucocyte granules by a 
method employing acetone fractionation, gel 
filtration and ion-exchange chromatography. 
In [5,6] we described specific inhibitors of por- 
cine elastase (PPE) and presented evidence sug- 
gesting that two distinct modes of binding to the 
active site of the enzyme were available to these 
protected dipeptide inhibitors. Here we have ex- 
tended the investigation of the enzyme inhibitor in- 
teractions involved in those binding modes and 
have used the further knowledge to enable the 
design of specific inhibitors of HLE. The most in- 
teresting compounds with potential for in vivo ap- 
plication are potent, water-soluble, reversibIe in- 
hibitors of HLE. 
HLE-QQM complex was prepared by incubation 
of human ~~-macroglobulin with a 3.4-fold mofar 
excess of purified HLE. The complex was purified 
by ge1 filtration. Human bronchial lavage was 
kindly donated by Dr T. Tetley (Charing Cross 
Hospital, London). Assays for elastase activity us- 
ing the substrates succinyl(. Ala.)3pnitroanilide 
[7], methoxysuccinyl(. Ala. )3. Pro. Val .p-nitroani- 
lide 181 and bovine ligamentum elastin 191 were per- 
formed using standard procedures. Inhibition con- 
stants were determined from Dixon plots. 
* To whom correspondence should be addressed 
Lung retention was determined by the recovery 
of ‘*C-Iabelled compound from excised lungs at in- 
tervals following intratracheal (i.t.) adminis- 
tration. 
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Pig.1. Synthesis of N”-(l-adamantanesulphonyl)-N’-(4-carboxybenzoyl)-L-lysyl-L-alanyl-L-valinal (compound 3). 
Acute (24 h) lung haemorrhage was induced in 
hamster lungs by intratracheal administration of 
purified HLE and the haemorrhage quantitated by 
assay of the total haemoglobin content of the ex- 
cised and homogenised lungs. Emphysema in 
hamsters induced by chronic administration of 
purified HLE was assessed histologically. 
3. RESULTS AND DISCUSSION 
In 1970 Thompson and Blout [lo] and Atlas et 
al. [l I] showed that PPE possesses an extended ac- 
tive site composed of 6 or 7 binding subsites. Oc- 
cupation of subsite S4 (nomenclature of Schechter 
and Berger [12]) by a substrate is particularly im- 
portant for substrate binding and catalytic activity. 
We have previously reported studies using PPE in- 
hibitors of general structure Pd. Ala. Pro. PI which 
emphasise the P&S4 interactions [5]. We also 
demonstrated that P4 and PI are interdependent in 
determining inhibitory potency. Relatively large 
groups can be accommodated at either position 
providing the other group is small. When both 
groups are large the compounds are inactive. We 
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have related this structure activity data for these 
inhibitors to the information on the active site of 
PPE obtained by X-ray diffraction studies. 
Moreover, comparative X-ray crystallographic 
studies, using propionyl . Ala. Pro. ethylamide (1) 
and propionyl . Ala. Pro. cyclopentylamide (2) 
separately bound to PPE, provided direct evidence 
for two binding modes. 
We have examined possible enzyme inhibitor in- 
teractions for each of the binding modes, using 
computerised molecular graphics techniques. This 
indicates that both compounds may bind through 
3 hydrogen bonds to enzyme atoms, N.214, N.216 
and 0.216 (fig.2, details to be published, N. 
Borkakoti and A. Krohn). Similar binding has 
been observed for other inhibitors of serine pro- 
teases [ 131. The differences in the conformations 
of the bound compounds (1,2) are attributed to the 
adjustment required for the cyclopentylamide (2) 
to enable the cyclopentyl group to avoid collision 
with the side-chain of Val.216. In this conforma- 
tion (fig.2b) the putative hydrogen bond between 
the N-terminal amide and 0.216 fixes Pq close to 
residues around .Arg2”*. ; this limits the size of 
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Fig.2. Binding modes of inhibitors to porcine pancreatic 
elastase, (a) compound 1; (b) compound 2. 
acceptable Pq residues. In comparative studies of 
HLE and PPE inhibition we have demonstrated 
that the interdependence of P4 and PI for PPE in- 
hibitors does not apply to HLE. Effective inhibi- 
tion of this enzyme is obtained with protected 
dipeptides in which both P4 and Pl are large 
groups [5]. This suggests that in HLE residues 
around 216 have more space for PI binding than in 
the case of PPE; this could arise from residue 216 
having a smaller side chain. This is consistent with 
the wider PI substrate specificity of HLE 1141. In 
addition we have synthesised compounds lacking 
the P4-Pa amide group to assess its contribution to 
inhibitor binding to HLE. In contrast to PPE, we 
find that inhibitory potency against HLE is 
enhanced when this amide function is replaced by 
sulphonamide or by a methylene bridge, but the 
other replacements which were investigated were 
less effective. Hydrogen bonding between the 
P4-P3 amide and the enzyme is clearly of less im- 
portance for inhibitor binding to HLE. 
These concepts produced relatively potent, 
reversible, HLE-specific inhibitors such as N4 
(1 -adamantanesulphonyl) . Ala. Pro. anilide (Ki 5.2 
FM). However, these compounds, like most other 
HLE inhibitors which have been described, are 
lipophilic. 
An HLE inhibitor with potential for use in 
human therapy must have not only good potency 
in vitro, but also suitable characteristics for in vivo 
activity. This requires a reasonable prospect for 
retention without rapid degradation in the lung. 
Earlier work by Schanker [15] has shown that 
lipophilic compounds deposited in the lung are 
cleared rapidly. This is consistent with our 
observations with adamantane sulphonyl . Ala. 
Pro. anilide, a strongly lipophilic compound; the 
lung-retention half-life in rodents was approx. 
2 min, following intratracheal (i.t.) administra- 
tion. We have sought to increase the lung retention 
time by increasing the hydrophilicity and the 
molecular size of the HLE inhibitor [15]. This was 
achieved by replacing the alanine residue in the 
dipeptide series by acylated-lysyl functions (table 
1); by utilising dicarboxylic acids, compounds with 
good potency and water solubility were obtained. 
The potency of these water-soluble inhibitors 
has been enhanced by replacing the C-terminal 
amide with a valinal residue. The aldehyde func- 
tion was clearly suggested by earlier work on in- 
hibitors of serine proteases; the interaction of the 
serine hydroxyl with this aldehyde group is 
presumed to give a tetrahedral analogue of the 
transition state intermediate involved in peptide 
bond cleavage [16]. The choice of valinal was sug- 
gested by HLE substrate studies but other 
aldehydes corresponding to neutral amino acids 
can be substituted. As in the case of our earlier 
studies with PPE inhibitors [5], we found that the 
proline residue in the PZ position could be replaced 
by an alanine residue in the HLE inhibitor, 
without significant change in potency. The alanine 
residue had the advantage, however, of facilitating 
the preparation of crystalline intermediates. 
Two compounds, N”-(l-adamantanesulphonyl)- 
Il”-(4-carboxybenzoyl)-L-lysyl-L-alanyl-L-valinal 
(compound 3) and N”-( l-adamantanesulphonyl)- 
w-succinyl-L-lysyl-L-prolyl-L-valinal (compound 
4), have been selected for further investigations. 
They inhibit not only HLE itself but also the en- 
zyme complexed with human at-macroglobulin 
203 
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Table 1 Table 2 
Modification of protected dipeptide inhibitors to obtain 
water solubility and increased potency 
Inhibition of elastases by compounds 3 and 4 
Inhibitor structure 150 value @M) 
against HLE. 
Succ~Aia)3pNA 
as substrate 
Elastase Inhibition constant 
Ki @MI 
Ads02 . Ala. Pro. NHPh 
Ads02 . Lys . Pro. NHPh 
z 
I 
7a 
54 
Ads02 . Lys . Pro. NHPh 
CO(CH&COOH 
I 
9 
Compound Compound 
3 4 
Human leucocyte elastase 0.06 0.11 
HLE-cQM complex 
(residual elastase activity) 0.1 0.15 
Elastase activity of human 
bronchial lavage 0.03” 0.15= 
AdSO2. Lys . Pro. NHPh 
AdCHzCHs . Ala. Pro. NH’Bu 
H.Glu.OH 
1 
14 
IO 
HLE-elastin as substrate Iso 1.4pM Iso 1.2pM 
a This value varies several-fold between different lavage 
samples. The two compounds were assayed against 
different samples 
AdCHzCHt . Lys . Pro. NH’Bu 
CO(CH2)2COO~ 
I 
10 Substrate for K, determination was MeOSucc( . Ala _)2. 
Pro. Val . pNA 
AdSO2. Lys . Pro. Val . H 
CO(CH&COOH 
I 
0.08 
Ads02 . Lys . Ala. Vai . H 
(compound 4) 
0.1 
CO ‘,\ COOH I 0 
AdSOz . Lys . Ala. Val . H 
(compound 3) 
0.08 
a This compound at 1OOpM does not inhibit PPE 
N- and C-terminal groups are not restricted to those 
examples shown above. Here they are limited to 
facilitate comparison of the effect of other changes 
within the molecule 
a single intraperitoneal dose of 3.2 g/kg com- 
pound (4) to mice. Acute (24 h) lung oedema and 
haemorrhage can be induced in the hamster by a 
singie i.t. instillation of purified HLE. Both com- 
pounds block this response. Doses of compound 
(3) of lO,~g and 1 mg/animal i.t. given con- 
comitantly with, or 40 min prior to the enzyme 
respectively, inhibited lung haemorrhage by 90 and 
100%. Emphysema can be generated in the 
hamster by repeated i.t. instillation over several 
weeks of lower doses of purified HLE. Concomi- 
tant it. administration of compound (3), 
200 pg/animal, significantly inhibits development 
of the emphysema ssessed both histologically and 
by quasi-static lung compliance measurements. 
and the form(s) of elastase in human bronchial 
lavage (table 2), They are inactive at 100/1M 
against trypsin, chymotrypsin, cathepsin G, 
angiote~sin converting enzyme and guinea pig 
complement. 
This new family of water-soluble reversible in- 
hibitors of HLE appears to have potential for use 
in the treatment of pulmonary emphysema. Fur- 
ther details of the chemistry, biochemistry, phar- 
macology and pharmacokinetics of this new family 
of inhibitors will be reported in later publications. 
Intratracheal administration of “C-labelled 
compound (4) to the hamster showed a lung reten- 
tion half-life of 2 h. An intratracheal dose of 
50 mglkg of either compound was tolerated in the 
hamster. No overt toxicity was observed following 
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